BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:UCB readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies UCB's drugs run\, from ClinicalTr
 ials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06921850-92@assetmemo.bio
DTSTAMP:20261121T004509Z
DTSTART;VALUE=DATE:20261221
DTEND;VALUE=DATE:20261222
SUMMARY:Bimzelx (bimekizumab): Phase 3 readout est. (NCT06921850)
DESCRIPTION:Bimzelx (bimekizumab)\, phase 3\, Hidradenitis Suppurativa.\nSt
 udy: A Study to Assess the Pharmacokinetics and Safety of Bimekizumab in C
 hildren and Adolescents With Moderate to Severe Hidradenitis Suppurativa\n
 Estimated primary completion: 21 December 2026. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/bimekizumab#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT06921850
URL:https://assetmemo.bio/drug/bimekizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06506916-92@assetmemo.bio
DTSTAMP:20261121T004509Z
DTSTART;VALUE=DATE:20270309
DTEND;VALUE=DATE:20270310
SUMMARY:Bimzelx (bimekizumab): Phase 3 readout est. (NCT06506916)
DESCRIPTION:Bimzelx (bimekizumab)\, phase 3\, Psoriatic Arthritis.\nStudy: 
 A Study to Evaluate the Effect of Bimekizumab on Gene Expression Biomarker
 s in Study Participants With Moderate to Severe Plaque Psoriasis\nEstimate
 d primary completion: 9 March 2027. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/bimekizumab#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT06506916
URL:https://assetmemo.bio/drug/bimekizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05077904-8884@assetmemo.bio
DTSTAMP:20261121T004509Z
DTSTART;VALUE=DATE:20270329
DTEND;VALUE=DATE:20270330
SUMMARY:Staccato Alprazolam: Phase 3 readout est. (NCT05077904)
DESCRIPTION:Staccato Alprazolam\, phase 3\, Epilepsy.\nStudy: A Study to Te
 st the Efficacy and Safety of Staccato Alprazolam in Study Participants 12
  Years of Age and Older With Stereotypical Prolonged Seizures\nEstimated p
 rimary completion: 29 March 2027. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/staccato-alprazolam#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT05077904
URL:https://assetmemo.bio/drug/staccato-alprazolam#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07277660-1380@assetmemo.bio
DTSTAMP:20261121T004509Z
DTSTART;VALUE=DATE:20270517
DTEND;VALUE=DATE:20270518
SUMMARY:galvokimig: Phase 2 readout est. (NCT07277660)
DESCRIPTION:galvokimig\, phase 2\, Atopic Dermatitis.\nStudy: A Dose-rangin
 g Study to Evaluate the Efficacy\, Safety\, Pharmacokinetics\, and Pharmac
 odynamics of Galvokimig in Adult Study Participants With Atopic Dermatitis
 \nEstimated primary completion: 17 May 2027. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/galvokimig#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT07277660
URL:https://assetmemo.bio/drug/galvokimig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05064878-8885@assetmemo.bio
DTSTAMP:20261121T004509Z
DTSTART;VALUE=DATE:20271108
DTEND;VALUE=DATE:20271109
SUMMARY:Fintepla (Fenfluramine): Phase 3 readout est. (NCT05064878)
DESCRIPTION:Fintepla (Fenfluramine)\, phase 3\, Epilepsy.\nStudy: A Phase 3
  Study to Examine the Efficacy and Safety of ZX008 in Subjects With CDKL5 
 Deficiency Disorder.\nEstimated primary completion: 8 November 2027. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/fenfluramine#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT05064878
URL:https://assetmemo.bio/drug/fenfluramine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07219420-92@assetmemo.bio
DTSTAMP:20261121T004509Z
DTSTART;VALUE=DATE:20271227
DTEND;VALUE=DATE:20271228
SUMMARY:Bimzelx (bimekizumab): Phase 3 readout est. (NCT07219420)
DESCRIPTION:Bimzelx (bimekizumab)\, phase 3.\nStudy: A Study to Evaluate th
 e Efficacy and Safety of Bimekizumab in Study Participants With Palmoplant
 ar Pustulosis\nEstimated primary completion: 27 December 2027. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/bimekizumab#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT07219420
URL:https://assetmemo.bio/drug/bimekizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06668181-92@assetmemo.bio
DTSTAMP:20261121T004509Z
DTSTART;VALUE=DATE:20280412
DTEND;VALUE=DATE:20280413
SUMMARY:Bimzelx (bimekizumab): Phase 3 readout est. (NCT06668181)
DESCRIPTION:Bimzelx (bimekizumab)\, phase 3\, Psoriatic Arthritis.\nStudy: 
 An Open-label Study to Evaluate the Pharmacokinetics and Safety of Bimekiz
 umab in Pediatric Study Participants With Active Juvenile Idiopathic Arthr
 itis Subtypes Enthesitis-related Arthritis (Including Juvenile-onset Ankyl
 osing Spondylitis) and Juvenile Psoriatic Arthritis\nEstimated primary com
 pletion: 12 April 2028. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/bimekizumab#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT06668181
URL:https://assetmemo.bio/drug/bimekizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06425549-92@assetmemo.bio
DTSTAMP:20261121T004509Z
DTSTART;VALUE=DATE:20280821
DTEND;VALUE=DATE:20280822
SUMMARY:Bimzelx (bimekizumab): Phase 3 readout est. (NCT06425549)
DESCRIPTION:Bimzelx (bimekizumab)\, phase 3\, Psoriasis.\nStudy: A Study to
  Evaluate the Efficacy and Safety of Bimekizumab Compared to Ustekinumab i
 n Children and Adolescents From 6 Years to Less Than 18 Years of Age With 
 Moderate to Severe Plaque Psoriasis\nEstimated primary completion: 21 Augu
 st 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/bimekizumab#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0642
 5549
URL:https://assetmemo.bio/drug/bimekizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05076617-8884@assetmemo.bio
DTSTAMP:20261121T004509Z
DTSTART;VALUE=DATE:20281130
DTEND;VALUE=DATE:20281201
SUMMARY:Staccato Alprazolam: Phase 3 readout est. (NCT05076617)
DESCRIPTION:Staccato Alprazolam\, phase 3\, Epilepsy.\nStudy: A Study to Te
 st the Safety and Tolerability of Staccato Alprazolam in Study Participant
 s 12 Years of Age and Older With Stereotypical Prolonged Seizures\nEstimat
 ed primary completion: 30 November 2028. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/staccato-alprazolam#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT05076617
URL:https://assetmemo.bio/drug/staccato-alprazolam#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07503444-8885@assetmemo.bio
DTSTAMP:20261121T004509Z
DTSTART;VALUE=DATE:20290206
DTEND;VALUE=DATE:20290207
SUMMARY:Fintepla (Fenfluramine): Phase 3 readout est. (NCT07503444)
DESCRIPTION:Fintepla (Fenfluramine)\, phase 3\, Rett Syndrome.\nStudy: A Ph
 ase 3 Study of Fenfluramine Hydrochloride in Rett Syndrome\nEstimated prim
 ary completion: 6 February 2029. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/fenfluramine#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT07503444
URL:https://assetmemo.bio/drug/fenfluramine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07720375-1380@assetmemo.bio
DTSTAMP:20261121T004509Z
DTSTART;VALUE=DATE:20290228
DTEND;VALUE=DATE:20290301
SUMMARY:galvokimig: Phase 2 readout est. (NCT07720375)
DESCRIPTION:galvokimig\, phase 2.\nStudy: A Study of 24 to 52 Weeks Treatme
 nt to Evaluate The Efficacy And Safety of Galvokimig in Adult Study Partic
 ipants With Non-Cystic Fibrosis Bronchiectasis\nEstimated primary completi
 on: 28 February 2029. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /galvokimig#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT07720375
URL:https://assetmemo.bio/drug/galvokimig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07725939-1380@assetmemo.bio
DTSTAMP:20261121T004509Z
DTSTART;VALUE=DATE:20290629
DTEND;VALUE=DATE:20290630
SUMMARY:galvokimig: Phase 2 readout est. (NCT07725939)
DESCRIPTION:galvokimig\, phase 2.\nStudy: A Study of 24 to 52 Weeks Treatme
 nt to Evaluate The Efficacy And Safety of Galvokimig in Study Participants
  With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD) With
  Chronic Bronchitis\nEstimated primary completion: 29 June 2029. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/galvokimig#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT07725939
URL:https://assetmemo.bio/drug/galvokimig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06315322-8844@assetmemo.bio
DTSTAMP:20261121T004509Z
DTSTART;VALUE=DATE:20291116
DTEND;VALUE=DATE:20291117
SUMMARY:Brivaracetam: Phase 3 readout est. (NCT06315322)
DESCRIPTION:Brivaracetam\, phase 3\, Epilepsy.\nStudy: A Study to Test the 
 Long-term Safety and Tolerability of Brivaracetam in Study Participants Wi
 th Childhood Absence Epilepsy or Juvenile Absence Epilepsy\nEstimated prim
 ary completion: 16 November 2029. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/brivaracetam#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT06315322
URL:https://assetmemo.bio/drug/brivaracetam#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04715646-8844@assetmemo.bio
DTSTAMP:20261121T004509Z
DTSTART;VALUE=DATE:20300708
DTEND;VALUE=DATE:20300709
SUMMARY:Brivaracetam: Phase 3 readout est. (NCT04715646)
DESCRIPTION:Brivaracetam\, phase 3\, Epilepsy.\nStudy: A Study to Test the 
 Safety and Tolerability of Brivaracetam in Children and Adolescents With S
 eizures\nEstimated primary completion: 8 July 2030. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/brivaracetam#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT04715646
URL:https://assetmemo.bio/drug/brivaracetam#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
